These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 18499572)

  • 21. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study.
    Armstrong PW;
    Eur Heart J; 2006 Jul; 27(13):1530-8. PubMed ID: 16757491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial.
    de Lemos JA; Gibson CM; Antman EM; Murphy SA; Morrow DA; Schuhwerk KC; Schweiger M; Coussement P; Van de Werf F; Braunwald E;
    Am Heart J; 2001 Apr; 141(4):592-8. PubMed ID: 11275925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab. The SCVIR Consultants' Conference; May 22, 2000; Orlando, FL. Society for Cardiovascular and Interventional Radiology.
    Benenati J; Shlansky-Goldberg R; Meglin A; Seidl E;
    J Vasc Interv Radiol; 2001 Jul; 12(7):795-805. PubMed ID: 11435535
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical utility of serial and continuous ST-segment recovery assessment in patients with acute ST-elevation myocardial infarction: assessing the dynamics of epicardial and myocardial reperfusion.
    Krucoff MW; Johanson P; Baeza R; Crater SW; Dellborg M
    Circulation; 2004 Dec; 110(25):e533-9. PubMed ID: 15611375
    [No Abstract]   [Full Text] [Related]  

  • 25. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.
    Kaul P; Armstrong PW; Cowper PA; Eisenstein EL; Granger CB; Van de Werf F; Mark DB
    Am Heart J; 2005 Apr; 149(4):637-44. PubMed ID: 15990746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial.
    Fernández-Avilés F; Alonso JJ; Peña G; Blanco J; Alonso-Briales J; López-Mesa J; Fernández-Vázquez F; Moreu J; Hernández RA; Castro-Beiras A; Gabriel R; Gibson CM; Sánchez PL;
    Eur Heart J; 2007 Apr; 28(8):949-60. PubMed ID: 17244641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefical effects of reteplase in combination with abciximab: platelet/leukocyte interactions and coagulation system.
    Szabo S; Walter T; Etzel D; Ehlers R; Kazmaier S; Beyer ME; Hoffmeister HM
    Int J Clin Pharmacol Res; 2003; 23(2-3):37-40. PubMed ID: 15018016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired myocardial perfusion score and inflammatory markers in patients undergoing primary angioplasty for acute myocardial infarction.
    Exaire JE; Fathi RB; Brener SJ; Karha J; Ellis SG; Bhatt DL
    Arch Cardiol Mex; 2006; 76(4):376-82. PubMed ID: 17315613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased fibrin specificity and reduced paradoxical thrombin activation of the combined thrombolytic regimen with reteplase and abciximab versus standard reteplase thrombolysis.
    Szabo S; Etzel D; Ehlers R; Walter T; Kazmaier S; Helber U; Beyer ME; Hoffmeister HM
    Drugs Exp Clin Res; 2004; 30(2):47-54. PubMed ID: 15272642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Local logistics guided management of acute ST elevation myocardial infarction: need of the hour.
    Chugh SK
    J Indian Med Assoc; 2009 Sep; 107(9):601-2. PubMed ID: 20337238
    [No Abstract]   [Full Text] [Related]  

  • 31. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators.
    Schömig A; Kastrati A; Dirschinger J; Mehilli J; Schricke U; Pache J; Martinoff S; Neumann FJ; Schwaiger M
    N Engl J Med; 2000 Aug; 343(6):385-91. PubMed ID: 10933737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction.
    Gibson CM; Karha J; Murphy SA; de Lemos JA; Morrow DA; Giugliano RP; Roe MT; Harrington RA; Cannon CP; Antman EM; Califf RM; Braunwald E;
    J Am Coll Cardiol; 2004 Apr; 43(7):1170-6. PubMed ID: 15063425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction.
    Martínez-Ríos MA; Rosas M; González H; Peña-Duque MA; Martínez-Sánchez C; Gaspar J; García H; Gaxiola E; Delgado L; Carrillo J; Leyva JL; Lupi E;
    Am J Cardiol; 2004 Feb; 93(3):280-7. PubMed ID: 14759375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful Treatment of Myocardial Infarction in an Infant With Kawasaki Disease.
    Jone PN; Tapia D; Davidson J; Fagan TE; Browne L; Ing RJ; Kay J
    Semin Cardiothorac Vasc Anesth; 2015 Sep; 19(3):255-9. PubMed ID: 25700695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on management of acute myocardial infarction: facilitated percutaneous coronary intervention.
    Futterman LG; Lemberg L
    Am J Crit Care; 2000 Jan; 9(1):70-6. PubMed ID: 10631393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "Drip-and-ship," "Stay-and-pray," "Freight-and-wait (and possibly inflate)" or simply opening the window wider?: Decision-making regarding time delays in the treatment of ST elevation MI.
    Uretsky BF
    Catheter Cardiovasc Interv; 2009 Sep; 74(3):406-7. PubMed ID: 19681117
    [No Abstract]   [Full Text] [Related]  

  • 37. Future of reperfusion therapy for acute myocardial infarction.
    White HD
    Lancet; 1999 Aug; 354(9180):695-7. PubMed ID: 10475175
    [No Abstract]   [Full Text] [Related]  

  • 38. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials.
    De Luca G; Suryapranata H; Stone GW; Antoniucci D; Tcheng JE; Neumann FJ; Bonizzoni E; Topol EJ; Chiariello M
    J Am Coll Cardiol; 2006 Feb; 47(3):685-6. PubMed ID: 16458158
    [No Abstract]   [Full Text] [Related]  

  • 39. Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial).
    Taglieri N; Saia F; Guiducci V; Tondi S; Conrotto F; Marrozzini C; Rocchi G; Biagini E; Reggiani ML; Giacometti P; Piovaccari G; Manari A; Marzocchi A;
    Am J Cardiol; 2009 Mar; 103(6):785-90. PubMed ID: 19268732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Half-dose recombinant tissue plasminogen activator plus abciximab for stroke.
    Walls RM; Birnbaumer D
    Acad Emerg Med; 2004 Dec; 11(12):1368; author reply 1368-9. PubMed ID: 15576532
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.